10-Q 1 f10q0612_oxysure.htm QUARTERLY REPORT f10q0612_oxysure.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 10-Q

x  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2012

o  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-54137
OXYSURE SYSTEMS, INC.
(Exact name of registrant as specified in its charter) 
 
Delaware
 
71-0960725
(State or other jurisdiction of
 
(IRS Employer
incorporation or organization)
 
Identification No.)
 
10880 John W. Elliott Drive, Suite 600, Frisco, TX  75033
(Address of principal executive offices)
 
(972) 294-6450
(Registrant’s telephone number)
 
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes þ No o
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes þ No ¨
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
 o
Accelerated filer
 o
Non-accelerated filer
 o
Smaller reporting company
 þ
(Do not check if a smaller reporting company)
   
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ¨ No þ
 
Our common stock is traded in the over-the-counter market and quoted on the Over-The-Counter Bulletin Board under the symbol “OXYS.”
 
The aggregate market value of the issuer’s common stock held by non-affiliates of the registrant as of August 10, 2012, was approximately $3,031,820 based on $.88, the per share price at which the registrant’s common stock was last sold on that date.
 
The number of shares outstanding of the registrant’s class of $0.0004 par value common stock as of August 10, 2012 was 20,717,722.
 
 
 

 
 
INDEX
 
     
Page
     
Number
       
PART I - FINANCIAL INFORMATION
   
       
Item 1.
Financial Statements (Unaudited)
 
1
 
Condensed Balance Sheet – June 30, 2012 and December 31, 2011
 
1
 
Condensed Statement of Operations – For the three and six months ended June 30, 2012 and 2011
 
2
 
Condensed Statement of Equity – As of and for the three months ended June 30, 2012
 
3
 
Condensed Statements of Cash Flows – For the six months ended June 30, 2012 and 2011
 
4
 
Condensed Notes to Financial Statements
 
5 - 31
Item 2.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
 
32
Item 3.
Quantitative and Qualitative Disclosures about Market Risk
 
39
Item 4.
Controls and Procedures
 
39
       
PART II - OTHER INFORMATION
   
       
Item 1.
Legal Proceedings
 
40
Item 1A.
Risk Factors
 
40
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
 
40
Item 3.
Defaults upon Senior Securities
 
40
Item 4.
(Removed and reserved)
 
40
Item 5.
Other Information
 
40
Item 6.
Exhibits
 
40
       
SIGNATURES
 
41
 
 
 

 
 
PART I - FINANCIAL INFORMATION

ITEM 1.                      FINANCIAL STATEMENTS
 
OXYSURE SYSTEMS INC.
 
BALANCE SHEETS
 
   
June 30, 2012
   
December 31, 2011
 
   
Unaudited
       
ASSETS
           
Current assets
           
Cash and cash equivalents
  $ 22,152     $ 65,118  
Accounts receivable, net of allowances for sales returns and allowance for doubtful accounts
    11,128       2,758  
Inventories
    247,838       247,956  
Prepaid expenses and other current assets
    -       -  
Total current assets
    281,118       315,833  
                 
Property and equipment, net
    51,841       133,659  
Intangible assets, net
    430,285       445,168  
Other assets
    53,274       53,274  
                 
TOTAL ASSETS
  $ 816,519     $ 947,934  
                 
LIABILITIES AND STOCKHOLDERS’ EQUITY
               
Current liabilities
               
Accounts payable and accrued expenses
  $ 231,161     $ 245,340  
Capital leases - current
    324,067       327,939  
Notes payable - current
    2,366,068       1,565,059  
Deferred revenue
    577,326       421,713  
Total current liabilities
    3,498,622       2,560,051  
                 
Long-term liabilities
               
Capital leases
  $ 2,632     $ 2,632  
Notes payable
    143,737       1,162,390  
Total long-term liabilities
    146,369       1,165,022  
                 
TOTAL LIABILITIES
    3,644,991       3,725,073  
                 
COMMITMENTS AND CONTINGENCY (NOTE 9)
               
                 
STOCKHOLDERS’ EQUITY
               
Preferred stock, par value $0.0005 per share; 25,000,000 shares authorized;
               
1,118,750 Series A convertible preferred shares issued and outstanding as of June 30, 2012 and 3,126,434 shares issued and outstanding as of December 31, 2011.
     559        1,563  
Common stock, par value $0.0004 per share; 100,000,000 shares authorized;
               
20,533,812  Shares of voting common stock issued and outstanding as of June 30, 2012 and 16,519,865 shares issued and outstanding as of December 31, 2011.
    8,214       6,608  
Additional Paid-in Capital
    11,137,373       10,645,347  
Accumulated deficit
    (13,974,618 )     (13,430,659 )
                 
   TOTAL STOCKHOLDERS’ EQUITY AND COMPREHENSIVE INCOME
    (2,828,472 )     (2,777,139 )
                 
TOTAL LIABILITIES  AND STOCKHOLDERS’ EQUITY
  $ 816,519     $ 947,934  
 
See accompanying notes to financial statements
 
 
1

 
 
OXYSURE SYSTEMS INC.
 
STATEMENTS OF OPERATIONS AND ACCUMULATED DEFICIT
 
(Unaudited)
 
                         
   
For the three months ended June 30,
   
For the six months ended June 30,
 
   
2012
   
2011
   
2012
   
2011
 
         
Restated
             
                         
Revenues, net
  $ 62,891     $ 62,522     $ 90,775     $ 98,551  
Cost of goods sold
    25,156       31,932       37,859       59,503  
Gross profit
    37,735       30,590       52,916       39,048  
                                 
Operating expenses
                               
Selling, general and administrative
    256,754       265,336       540,276       550,544  
Loss from operating expenses
    (219,019 )     (234,746 )     (487,360 )     (511,497 )
                                 
Other income (expenses)
                               
   Other income (expense)
    58,009       -       58,718       33,750  
Interest expense
    (57,462 )     (228,622 )     (115,316 )     (359,708 )
Total other income (expenses)
    547       (228,622 )     (56,599 )     (325,958 )
                                 
Net loss
    (218,472 )     (463,371 )     (543,958 )     (837,455 )
                                 
Accumulated deficit - beginning of the period
  $ (13,756,109 )   $ (12,272,344 )   $ (13,430,659 )   $ (11,898,260 )
Prior period adjustments
    (36 )     -       -       -  
                                 
Accumulated deficit - end of the period
  $ (13,974,618 )   $ (12,735,715 )   $ (13,974,618 )   $ (12,735,715 )
                                 
Basic net income (loss) per common share
  $ (0.01 )   $ (0.03 )   $ (0.03 )   $ (0.05 )
Diluted net income (loss) per common share
  $ (0.01 )   $ (0.03 )   $ (0.03 )   $ (0.05 )
                                 
Weighted average common shares outstanding:
                               
Basic
    19,807,432       15,749,756       18,825,947       15,739,344  
Diluted
    19,807,432       15,749,756       18,825,947       15,739,344  
 
See accompanying notes to financial statements
 
 
2

 
 
OXYSURE SYSTEMS, INC.
 
STATEMENT OF STOCKHOLDERS' EQUITY
 
AS OF AND FOR THE PERIOD ENDED JUNE 30, 2012
 
(Expressed in US Dollars)
 
 
                            Warrant issuance     Additional Paid In Capital - Preferred Stock       Additional Paid In Capital - Warrants and Options       Additional Paid In Capital     Deficit Accumulated     Total Stockholders' Equity (Deficit)  
   
Convertible
                                     
   
Preferred Stock
   
Common Stock
                         
   
Shares
   
Par Value
   
Shares
   
Par Value
                         
Balance as of March 31, 2012
    1,318,750       659       18,934,510       7,574       132,750       1,407,621       4,511,015       4,854,820       (13,756,109 )     (2,841,669 )
                                                                                 
 - Common Stock options exercised
                    356,474       143                               88,976               89,119  
 - Common Stock warrants exercised
                    882,616       353       (85,000 )                     90,753               6,106  
 - Common Stock issued upon conversion of convertible preferred stock
    (200,000 )     (100 )     244,000       98               (199,900 )             199,902               -  
 - Common Stock issued upon conversion of convertible notes
                    116,212       46                               128,740               128,787  
 - Common Stock options issued for compensation
                                                    7,695                       7,695  
 - Common Stock options and warrants issued for services
                                                                            -  
 - Common Stock warrants issued in connection with convertible loans
                                                                            -  
 - Prior period adjustment: correction to accounting error
                                                                    (36 )     (36 )
                                                                                 
Net Loss for period ending June 30, 2012
                                                                    (218,472 )     (218,472 )
                                                                                 
Balance as of June 30, 2012
    1,118,750       559       20,533,812       8,214       47,750       1,207,721       4,518,710       5,363,192       (13,974,618 )     (2,828,472 )
 
See accompanying notes to financial statements
 
 
3

 
 
OXYSURE SYSTEMS INC.
 
STATEMENTS OF CASH FLOWS
 
(Unaudited)
 
   
Six Months Ended June 30,
 
   
2012
   
2011
 
CASH FLOWS FROM OPERATING ACTIVITIES:
           
Net loss
  $ (543,958 )     (837,455 )
Adjustments to reconcile net income to net
               
cash used in operating activities
               
Depreciation
    81,818       88,616  
Amortization of intangible assets
    14,883       14,883  
Impairment of intangible assets
    -       -  
Amortization of debt discount and warrant fair values related to convertible notes
    104,611       325,112  
Amortization of other assets
    6,206       3,310  
Changes in Deferred Rent and Leasehold Improvement Allowance
    (43,386 )     (41,361 )
Issuance of common stock options to employees as
               
   compensation
    17,209       41,470  
Issuance of common stock options and warrants in exchange
               
   for services
    -       32,023  
Changes in current assets and liabilities
               
Accounts receivable
    (8,370 )     (10,294 )
Inventory
    118       (20,669 )
Prepaid expenses and other current assets
    -       (5,420 )
Accounts payable and accrued liabilities
    32,985       30,060  
Deferred revenue
    155,613       39,180  
                 
NET CASH USED IN OPERATING ACTIVITIES
    (182,273 )     (340,545 )
 
               
CASH FLOWS FROM INVESTING ACTIVITIES
               
Purchases of intangible assets
    -       (1,231 )
Other assets
    -       (189 )
                 
NET CASH USED IN INVESTING ACTIVITIES
    -       (1,420 )
                 
CASH FLOWS FROM FINANCING ACTIVITIES
               
Loan proceeds
    47,953       377,482  
Payment of capital leases
    (3,871 )     (17,256 )
Issuance of Common Stock
    -       -  
Proceeds from exercise of common stock options and warrants
    95,225       18,800  
                 
NET CASH PROVIDED BY FINANCING ACTIVITIES
    139,307       379,026  
                 
Net increase (decrease) in cash and cash equivalents
    (42,966 )     37,061  
                 
Cash and cash equivalents, at beginning of period
    65,118       39,887  
                 
Cash and cash equivalents, at end of period
  $ 22,152       76,947  
                 
Supplemental disclosure of cash flow information:
               
Cash paid during the period for:
               
Interest
  $ 721       4,997  
Income taxes
  $ -       -  
                 
Supplemental non-cash investing and financing activities:
               
Promissory subordinated convertible notes converted to common stock
  $ 354,563       -  
Shareholder loans converted to common stock
  $ 25,622       -  
Issuance of common stock warrants in connection with convertible loans
  $ -       289,292  
Promissory subordinated convertible notes issued in connection with rent agreements
  $ -       100,000  
 
See accompanying notes to financial statements
 
 
4

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A summary of significant accounting policies of OxySure® Systems, Inc. (“OxySure,” “we,” “us,” “our,” or the “Company”) is presented to assist in understanding our financial statements. The accounting policies presented in these footnotes conform to accounting principles generally accepted in the United States of America and have been consistently applied in the preparation of the accompanying financial statements. These financial statements and notes are representations of the Company’s management who are responsible for their integrity and objectivity.

OxySure was incorporated on January 15, 2004 as a Delaware corporation. The Company is located in Frisco, Texas and is a medical technology company focused on the design, manufacture and distribution of specialty respiratory products.  The Company and its founder have developed a unique catalytic process and methodology to generate medically pure (USP) oxygen instantly from two dry, inert powders. The Company has been issued nine patents on this technology, and it has several additional patents pending. On December 9, 2005, the Company received approval from the Food and Drug Administration (510K, Class II) for its first product utilizing this technology. This product is referred to as the OxySure® Portable Emergency Oxygen System, Model 615, (or Model 615 for short) and the FDA approval is for over-the-counter purchase (without the need of a prescription).

The Company has, at the present time, not paid any dividends and any dividends that may be paid in the future will depend upon the financial requirements of the Company and other relevant factors.

On July 19, 2004, the Company affected a 1-for-5 reverse stock split of the Company’s common stock. All share numbers and common stock numbers, including stock options and warrants, have been retroactively adjusted to reflect the reverse stock split.

While the Company has effectively managed its working capital deficit the going concern risk remains an issue for the company to manage.  The Company has implemented, and plans to further implement several different strategies in order to help the Company ease the going concern issue.  Refer to Note 15, “Going concern” of Notes to Reviewed Financial Statements for a partial list of the Company’s plans to mitigate the going concern issue.
 
Basis of Presentation - The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company’s system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) all valid transactions are recorded; and (3) transactions are recorded in the period in a timely manner to produce financial statements which present fairly the financial condition of the Company.  The interim financial statements include all adjustments which, in the opinion of management, are necessary in order to make the financial statements not misleading.
 
 
5

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Use of estimates - The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reported period.  Actual results could differ from those estimated.
 
Revenue Recognition - We recognize revenue when persuasive evidence of an arrangement exists, shipment has occurred, the price is fixed or determinable, and collectability is reasonably assured.  Revenues are recognized from product sales, net of discounts and rebates.  This revenue recognition policy is applied to both customers and distributors.
 
Fees from licensees desiring to manufacture and distribute our products or derivative products using our intellectual property include initial license fees and royalties.  Initial license fees are generally recognized upon granting of the license to the licensee.  Royalties are recognized in the period earned.

Deferred Revenue and Income - We defer revenue and income when we invoice a customer or a customer makes a payment and the requirements of revenue recognition have not been met (i.e. persuasive evidence of an arrangement exists, shipment from a company warehouse has occurred, the price is fixed or determinable and collectability is reasonably assured). Deferred Revenue was $577,326 and $421,713 as at June 30, 2012 and December 31, 2011, respectively.

Cash and Cash Equivalents - Cash consists of all highly liquid investments purchased with maturity of three months or less to be cash equivalents. Cash and cash equivalents may at times exceed Federally-insured limits. To minimize this risk, the Company places its cash and cash equivalents with high credit quality institutions.

Inventory – Our inventory consists of raw material and components for our portable oxygen systems as well as completed products and accessories.   Inventories are computed using the lower of cost or market, which approximates actual cost on a first-in first-out basis. Inventory components are parts, work-in-process and finished goods. Finished goods are reported as inventories until the point of title transfer to the customer. We write down our inventory value for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions. These factors are impacted by market and economic conditions, technology changes, new product introductions and changes in strategic direction and require estimates that may include uncertain elements. Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values. Management has established inventory reserves to cover estimated inventory losses for all work-in-process and finished goods related to products we manufactured, as well as raw material and components for those products that had no potential use in products to be manufactured in the future. Management is required to make judgments about the future benefit of our raw materials and components. Actual reserve requirements could differ significantly from Management’s estimates, which could have a significant unfavorable impact on our future gross margins.

Concentration of Credit Risk – We sell our products throughout the United States as well as in certain other countries.  Sales to its recurring customers in the United States are generally granted on net 30-day credit terms. We perform periodic credit evaluations of our recurring customers and generally do not require collateral. In general, we require prepayment on all sales to customers outside the United States. An allowance for doubtful accounts is maintained for potential credit losses, which losses historically have not been significant.
 
 
6

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
 
We invest our cash in deposits and money market funds with major financial institutions.  We place our cash investments in instruments that meet high credit quality standards, as specified in our investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issue, issuer or type of instrument.

Fair Value of Financial Instruments - Our financial instruments consist principally of cash and cash equivalents, accounts receivable and accounts payable.  We believe that the recorded values of all of our other financial instruments approximate their fair values because of their nature and respective maturity dates or durations. The fair value of our long-term debt is determined by using estimated market prices. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:

Level 1: Inputs are based on quoted market prices for identical assets or liabilities in active markets at the measurement date.
Level 2: Inputs include quoted prices for similar assets or liabilities in active markets and/or quoted prices for identical or similar assets or liabilities in markets that are not active near the measurement date.
Level 3: Inputs include management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation.

The fair value of the majority of our cash equivalents was determined based on “Level 1” inputs. We do not have any marketable securities in the “Level 2” and “Level 3” category. We believe that the recorded values of all our other financial instruments approximate their current fair values because of their nature and respective relatively short maturity dates or durations.

Property and Equipment – Property and equipment are recorded at cost with depreciation and amortization provided over the shorter of the remaining lease term or the estimated useful life of the improvement ranging from three to seven years. Renewals and betterments that materially extend the life of an asset are capitalized. Expenditures for maintenance and repairs are charged to expense when incurred. Furniture and fixtures are depreciated over five years. Machinery and equipments are depreciated over five to seven years. Software is depreciated over three years.  Leasehold improvements are computed using the shorter of the estimated useful lives of the assets or the lease terms.  Depreciation expense was $40,314 and $44,065 for the three month periods ended June 30, 2012 and 2011, respectively.

Other Long-Lived Assets – We have two types of intangible assets – patents and trademarks.  Intangible assets are carried at cost, net of accumulated amortization.  Amortization expense for patents and trademarks was $7,441 and $7,441 for the three month periods ended June 30, 2012 and 2011, respectively.

Intangible assets with definite useful lives and other long-lived assets are tested for impairment if certain impairment indicators are identified.  Management evaluates the recoverability of its identifiable intangible assets in accordance with applicable accounting guidance, which requires the assessment of these assets for recoverability when events or circumstances indicate a potential impairment exists. Certain events and circumstances the Company considered in determining whether the carrying value of identifiable intangible assets may not be recoverable include, but are not limited to: significant changes in performance relative to expected operating results; significant changes in the use of the assets; significant negative industry or economic trends; and changes in its business strategy.  In determining if impairment exists, we estimate the undiscounted cash flows to be generated from the use and ultimate disposition of these assets.  If impairment is indicated based on a comparison of the assets’ carrying values and the undiscounted cash flows, the impairment loss is measured as the amount by which the carrying amount of the assets exceeds the fair value of the assets. Impairment charges for patents were $0 for each of the three month periods ended June 30, 2012 and 2011.
 
 
7

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
 
Other Assets – We record Other Assets net of accumulated amortization. Amortization expense for Other Assets $0 for each of the three month periods ended June 30, 2012 and 2011.
 
Allowance for Doubtful Accounts - We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make payments.  We periodically review these allowances, including an analysis of the customers’ payment history and information regarding the customers’ creditworthiness.  Actual write-offs have not been materially different from the estimated allowance.

Research and Development Costs – Costs associated with the development of our products are charged to expense as incurred.  $1,175 and $60 were incurred in the three month periods ended June 30, 2012 and 2011, respectively.

Income Taxes - In accordance with Accounting Standards Codification (“ASC”) Topic 740, “Income Taxes” (“ASC 740”), we account for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our Consolidated Financial Statements, but have not been reflected in our taxable income.  A valuation allowance has been established to reduce deferred tax assets to their estimated realizable value.  Therefore, we provide a valuation allowance to the extent that we do not believe it is more likely than not that we will generate sufficient taxable income in future periods to realize the benefit of our deferred tax assets.  We recognize interest and penalties related to unrecognized tax benefits in income tax expense.
 
Equity Warrants - We issued warrants to purchase shares of our common stock in connection with convertible notes. In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the notes were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance. We record the fair value of the warrants at the time of issuance as additional paid in capital and as a debt discount to the notes.  We amortize this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrants with the convertible notes, a beneficial conversion option is recorded as a debt discount reflecting the incremental conversion option intrinsic value of the conversion option provided to the holders of the notes. We also amortize this debt discount as interest expense over the life of the notes.  The intrinsic value of each conversion option was calculated as the difference between the effective conversion price and the fair value of the common stock, multiplied by the number of shares into which the note is convertible.

Stock-Based Compensation – We account for share-based payments, including grants of stock options to employees, consultants and non-employees; moreover, we issue warrants to the consultants and related parties.  We are required to estimate the fair value of share-based awards and warrants on the date of grant. The value of the award is principally recognized as expense ratably over the requisite service periods. We have estimated the fair value of stock options and warrants as of the date of grant or assumption using the Black-Scholes option pricing model, which was developed for use in estimating the value of traded options that have no vesting restrictions and that are freely transferable. The Black-Scholes model requires the input of certain assumptions.  Changes in the assumptions used in Black-Scholes model can materially affect the fair value estimates. We evaluate the assumptions used to value stock options on an annual basis. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding.
 
 
8

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
 
The expected term is based on the observed and expected time to exercise and post-vesting cancellations of options by employees.  Upon the adoption of the accounting guidance, we continued to use historical volatility in deriving its expected volatility assumption as allowed under GAAP because we believe that future volatility over the expected term of the stock options is not likely to differ materially from the past. The risk-free interest rate assumption is based on 5-year U.S Treasury zero-coupon rates appropriate for the expected term of the stock options. The expected dividend assumption is based on the history and expectation of dividend payouts.  The fair values generated by the Black-Scholes model may not be indicative of the actual fair values of the equity awards, as we do not consider other factors important to those awards to employees, such as continued employment, periodic vesting requirements and limited transferability.  The amount of stock based compensation expenses is net of an estimated forfeiture rate, which is also based on historical data. For the three month periods ended June 30, 2012 and 2011, stock based compensation expense was approximately $7,695 and $5,056, respectively, which consisted primarily of stock-based compensation expense related to stock options issued to the employees and recognized under GAAP.

The Company follows ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees. In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services to be provided to the Company are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined. The Company recognizes this expense over the period in which the services are provided. For each of the three month periods ended June 30, 2012 and 2011, stock based compensation expense was approximately $0, which consisted primarily of stock-based compensation expense related to stock options and warrants recognized under GAAP issued to consultants and other non-employees.

The following table shows the components of the Company’s stock based compensation expense for employees, consultants and other non-employees:

   
Three months ended June 30,
 
   
2012
   
2011
 
             
Common Stock options issued for compensation
    7,695       5,065  
Common Stock options and warrants issued for services
    -       -  
                 
Total
    7,695       5,065  

Shipping and Handling Costs - Shipping and handling charges to customers are included in net revenues, and the associated costs incurred are recorded in cost of revenues.

Advertising Costs - Advertising costs are charged to operations when incurred.  We incurred $18,134 and $0 in advertising and promotion costs during the three month periods ended June 30, 2012 and 2011, respectively.
 
9

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Litigation and Settlement Costs - Legal costs are expensed as incurred. The Company records a charge equal to at least the minimum estimated liability for a loss contingency when both of the following conditions are met: (i) information available prior to issuance of the financial statements indicates that it is probable that an asset had been impaired or a liability had been incurred at the date of the financial statements and (ii) accrue the best estimate within a range of loss if there is a loss or, when there is no amount within a range that forms a better estimate, the Company will accrue the minimum amount in the range. The Company is subject to litigation in the normal course of business.

Loss Per Share - Basic loss per share, which excludes anti-dilutive securities, is computed by dividing loss available to common shareholders by the weighted-average number of common shares outstanding for that particular period. In contrast, diluted loss per share considers the potential dilution that could occur from other equity instruments that would increase the total number of outstanding shares of common stock. Such amounts include shares potentially issuable under outstanding options, warrants, convertible preferred stock and convertible notes.

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share follows:
 
   
Three months ended June 30,
 
   
2012
   
2011
 
Historical net loss per share:
           
             
Numerator
           
Net loss, as reported
    (218,472 )     (463,371 )
Less: Effect of amortization of interest expense on convertible notes
    -       -  
Net loss attributed to common stockholders (diluted)
    (218,472 )     (463,371 )
                 
Denominator
               
Weighted-average common shares outstanding
    19,807,432       15,749,756  
Effect of dilutive securities
    -       -  
Denominator for diluted net loss per share
    19,807,432       15,749,756  
Basic and diluted net loss per share
  $ (0.01 )   $ (0.03 )
 
The following outstanding options, warrants, convertible preferred shares and convertible note shares were excluded from the computation of basic and diluted net loss per share for the periods presented because including them would have had an anti-dilutive effect.

   
Three months ended June 30,
 
   
2012
   
2011
 
             
Options to purchase common stock
    1,554,530       2,064,354  
Warrants to purchase common stock
    1,872,034       2,932,909  
Common shares issuable upon conversion of convertible preferred stock
    1,364,875       3,814,249  
Convertible note shares outstanding
    1,696,331       2,304,419  
 
Restatements and Reclassifications - Certain financial statement items have been reclassified to conform to the current periods’ presentation.  These reclassifications had no impact on previously reported net loss. Certain financial statement items for the quarter ended June 30, 2011 have been restated - please see Note 17 - Correction of error to prior period financial statements.
 
 
10

 
 
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)
 
Recent Accounting Pronouncements

In June 2011, the Financial Accounting Standards Board, or FASB, issued guidance regarding the presentation of comprehensive income. The new standard requires the presentation of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The new standard also requires presentation of adjustments for items that are reclassified from other comprehensive income to net income in the statement where the components of net income and the components of other comprehensive income are presented. The updated guidance is effective on a retrospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. The adoption of this guidance will not have a material impact on our financial statements.
 
In May 2011 the FASB issued additional guidance on fair value measurements that clarifies the application of existing guidance and disclosure requirements, changes certain fair value measurement principles and requires additional disclosures about fair value measurements. The updated guidance is effective on a prospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. The adoption of this guidance will not have a material impact on our financial statements.

In September 2011 the FASB issued new accounting guidance intended to simplify goodwill impairment testing. Entities will be allowed to perform a qualitative assessment on goodwill impairment to determine whether a quantitative assessment is necessary. This guidance is effective for goodwill impairment tests performed in interim and annual periods for fiscal years beginning after December 15, 2011. Early adoption is permitted. The adoption of this guidance will not have a material impact on our financial statements.
 
 
11

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 2 – BALANCE SHEET COMPONENTS

   
June 30,
   
December 31,
 
   
2012
   
2011
 
             
Cash and cash equivalents:
           
Cash
    22,152       65,118  
Total cash and cash equivalents
  $ 22,152     $ 65,118  
                 
Inventories:
               
Total inventories
  $ 247,838     $ 247,956  
                 
Accounts Receivable, net of allowances
  $ 11,128     $ 2,758  
                 
Property and equipment, net:
               
Machinery and equipment
    919,736       919,736  
Leasehold improvements
    547,856       547,856  
Computer equipment and furniture and fixtures
    203,922       203,922  
Software
    10,691       10,691  
      1,682,204       1,682,204  
Accumulated depreciation and amortization
    (1,630,363 )     (1,548,545 )
Total property and equipment, net
  $ 51,841     $ 133,659  
                 
                 
Accounts payable and accrued expenses:
               
Leasehold Improvement Allowance
    16,323       48,969  
Accounts payable
    208,608       136,263  
Accrued interest
    -       40,094  
Other accrued liabilities
    6,230       20,015  
Total accounts payable and accrued expenses
  $ 231,161     $ 245,340  
 
NOTE 3 – INTANGIBLE ASSETS

We have two types of intangible assets: patents and trademarks. We capitalize expenditures associated with patents and trademarks related to our various technologies. Capitalized costs include amounts paid to third parties for legal fees, application fees and other direct costs incurred in the filing and prosecution of patent and trademark applications. These assets are amortized on a straight-line method over their legal life.
 
 
12

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 3 – INTANGIBLE ASSETS (CONTINUED)

Intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable in accordance with applicable accounting guidance. Impairment charges for patents were $0 for each of the three month periods ended June 30, 2012 and 2011.

On January 15, 2004, the Company executed an Asset Purchase and Stock Transfer Agreement with entities controlled by the founder of the Company. In connection with this agreement, the Company acquired certain assets, including certain rights, title and interest to intellectual property, relating to the oxygen method and apparatus, developed by the founder of the Company prior to January 15, 2004. As consideration for the purchase, the Company issued 14,000,000 shares of common stock and a promissory note for $150,000 to these entities. The common stock was valued at $7,000 using the par value of the common stock on the date of issuance, which approximates these entities’ basis (which is not indicative of fair value). The non-recourse promissory note bore interest at 6.5% per annum and was paid in full during 2006.

The carrying values of our amortized acquired intangible assets as of June 30, 2012 are as follows:

   
June 30, 2012
 
   
Gross
   
Accumulated Amortization and write off
   
Net
 
                   
Patents
  $ 610,518     $ (219,232 )   $ 391,286  
Trademarks
  $ 45,723     $ (6,724 )   $ 38,999  
    $ 656,241     $ (225,956 )   $ 430,285  
 
Of the net amount of $430,285 in intangible assets as of June 30, 2012, approximately 90.9% is in patents and 9.1% is in trademarks.  Included in the $656,241 gross amount for patents and trademarks is $157,000 acquired from entities controlled by the founder of the Company in January 2004. The remaining $499,241 represents amounts paid to third parties for legal fees, application fees and other direct costs incurred in the filing and prosecution of patent and trademark applications.
 
NOTE 4 – NOTES PAYABLE

We have issued warrants for the purchase of shares of our restricted common stock in connection with raising equity and debt financing and for other professional services.  The fair value of warrants issued is determined in accordance with Codification topic 470-20.

Frisco Promissory Note  On April 3, 2007 we entered into a note agreement with the City of Frisco, Texas for $243,000 (the “Frisco Note”) pursuant to an economic incentive package provided through the Frisco Economic Development Corporation (“FEDC”). The note required varying annual principal payments through August 2012.  The note was non-interest bearing; however, interest has been imputed at 12.18% per annum. The unamortized discount at December 31, 2010 was $66,198. Individual annual payments were to be forgiven if certain performance targets are achieved, which include the number of full time employees, square feet occupied in the city of Frisco and the taxable value of business and personal property in the City of Frisco. The first annual payment for 2008 in the amount of $30,000 was forgiven and we recognized the entire $30,000 under “Other income” in the Statement of Operations and Accumulated Deficit for the year ended December 31, 2008.  On March 22, 2011 we entered into an Amended and Restated Performance Agreement with the FEDC. In terms of the Amended and Restated Performance Agreement, the FEDC provided us with economic assistance in the form of the renewal and extension of the outstanding forgivable loan of $213,000 together with revised performance credits over 5 years, commencing on March 22, 2011 and ending on the earlier to occur of: (i) the full payment of the economic incentives; or (ii) March 31, 2016.
 
 
13

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)
 
The renewed Frisco Note requires varying annual principal payments through December 2015. The face value of the renewed note is $213,000, and the note is non-interest bearing; however, interest has been imputed at 12.34% per annum.

On December 1, 2011 we received the first performance credit from the FEDC in the amount of $26,000 pursuant to the Amended and Restated Performance Agreement. We recognized the entire $26,000 under “Other income” in the Statement of Operations and Accumulated Deficit for the year ended December 31, 2011. The unamortized discount at June 30, 2012 was $46,547. The net amount of the note as at June 30, 2012 was $140,454.

Future principal payments of this note payable are as follows:
 
2012
   
39,000
 
2013
   
44,000
 
2014
   
52,000
 
2015
   
52,000
 
   
$
187,000
 
 
Agave/JTR Subordinated, Convertible Notes  During March 2008, we completed a $1 million financing package consisting of a promissory note for $750,000 (“First Note”) and a promissory note with a draw down provision for $250,000 (“Second Note”) (collectively, the “Notes”). In March 2009 the First Note and the Second Note were modified by extending the maturity date in each case to April 15, 2010. On December 31, 2009, the First Note and the Second Note were further modified by extending the maturity date in each case to April 15, 2011.  In August 2010, the First Note and the Second Note were further modified by extending the maturity date in each case to April 15, 2012. In November 2011, the First Note and the Second Note were further modified by extending the maturity date in each case to April 15, 2013. The holder of the First Note is Agave Resources, LLC (“Agave”), and the President of Agave is Donald Reed, one of our Directors.  In connection with the First Note, on April 15, 2008 Agave was also issued penny warrants to purchase 350,000 shares of common stock.  The warrants are immediately exercisable and expire on April 15, 2013.  The holder of the Second Note is JTR Investments, Limited (“JTR”) a company controlled by Julian T. Ross, our founder.

As of December 31, 2008 the maximum of $250,000 has been drawn against the Second Note.  In connection with the Second Note, on December 31, 2008 JTR was also issued penny warrants to purchase 116,667 shares of common stock.  Both Notes are non-interest bearing.  The basis for issuing penny warrants in connection with the First Note and the Second Note include, but are not limited to, the fact that no interest is payable on the Notes, our ability to attract new investment at the time, market conditions and other factors.  Given these factors, the Board of Directors has deemed the terms of these transactions to be fair.  No third party fairness opinion was obtained in relation to these transactions.
 
 
14

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

Conversion Rights: At any time on or prior to the Maturity Date, subject to the written consent of the Company, all or any portion of the then outstanding Principal Amount and accrued but unpaid interest of the Notes may be converted (the "Optional Conversion") into a number of shares of the Company’s common stock (the "Optional Conversion Shares") equal to the amount of the then outstanding Principal Amount plus the then accrued but unpaid interest to be converted, divided by the Conversion Price which shall be $1.50 per Optional Conversion Share.

In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the First Note were allocated based on the relative fair value of the note without the warrant issued in conjunction with the note and of the warrant itself at the time of issuance. We recorded the relative fair value of the warrant issued to Agave in the amount of $346,936 as a debt discount upon issuance, and amortized this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental intrinsic value benefit of $96,936, at the time of issuance provided to the holder of the note, which was also amortized as interest expense over the life of the note. We recorded no interest expense for the three months ended June 30, 2012 and 2011 in connection with the First Note.

We recorded the relative fair value of the warrant issued to JTR in connection with the Second Note in the amount of $115,857 as a debt discount upon issuance, and expensed this amount as interest expense upon issuance.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental intrinsic value benefit of $32,254, at the time of issuance provided to the holder of the note, which was also expensed as interest expense upon issuance. We recorded no interest expense for the three months ended June 30, 2012 and 2011 in connection with the JTR Second Note.
 
 
15

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)

NOTE 4 – NOTES PAYABLE (CONTINUED)

JTR Senior, Convertible Note. In July, 2008, JTR agreed to provide the Company with additional working capital to fund continuing operations (the “Senior Note Interim Funding”).  On November 1, 2008 the Company’s Board agreed with JTR on the terms of a loan with a draw down provision of up to a maximum of $750,000.  This maximum amount was subsequently increased to $2,000,000 on March 30, 2011. This is a Senior Note (all the tranches under this facility, collectively, the “Senior Note”) with no interest payable.  All amounts advanced by JTR during the Senior Note Interim Funding are draw downs on the Senior Note.  In connection with the Senior Note, the Company will issue .47 penny warrants for every dollar drawn under this facility.  As of June 30, 2012, the outstanding balance under the Senior Note was $1,018,656.  The total number of penny warrants issued to JTR pursuant to the Senior Note up to and including June 30, 2012 was 572,503.  The basis for issuing penny warrants in connection with the Senior Note include, but are not limited to, the fact that no interest is payable on the note, the Company’s ability to attract new investment at the time, market conditions, the terms previously agreed to in connection with the First Note and Second Note, and other factors.  Given these factors, the Board of Directors has deemed the terms of this transaction to be fair.  No third party fairness opinion was obtained in relation to this transaction.

Conversion Rights: At any time on or prior to the Maturity Date, subject to the written consent of the Company, all or any portion of the then outstanding Principal Amount and accrued but unpaid interest of this Note may be converted (the "Optional Conversion") into a number of shares of the Company’s common stock (the "Optional Conversion Shares") equal to the amount of the then outstanding Principal Amount plus the then accrued but unpaid interest to be converted, divided by the Conversion Price which shall be $1.50 per Optional Conversion Share.
 
Maturity: The total amount outstanding under the Senior Note is classified as current.
 
In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the Senior Note were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance.  As of June 30, 2012 the Company recorded the relative fair values of the warrants issued to JTR in connection with the Senior Note in the amount of $546,477 as a debt discount upon each issuance, and expensed each debt discount as interest expense upon issuance.  Additionally, as a result of issuing the warrants with the convertible promissory notes, a beneficial conversion option was recorded as a debt discount on each note reflecting the incremental intrinsic value benefit totaling $162,842, at the time of each issuance provided to JTR in connection with the Senior Note up to an including June 30, 2012. The debt discount for each issuance under the Senior Note is expensed as interest expense upon issuance. We recorded interest expenses in the amounts of $0 and $137,079 for the three months ended June 30, 2012 and 2011, respectively, in connection with the Senior Note.
 
 
16

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

Sinacola Subordinated, Convertible Notes.
 
Third Landlord Note; Fourth Landlord Note:

On December 31, 2010 we entered into a second Rent Satisfaction Agreement (the “2010 RSA”) with our landlord, Sinacola Commercial Properties, Ltd. (“Sinacola”). In terms of the 2010 RSA, all of our outstanding rent obligations for the 2010 financial year under our lease agreement, up to and including December 31, 2010 including, but not limited to, base rent, deferred rent, and our share of operating costs, were satisfied in full.

We issued Sinacola two Promissory Notes pursuant to the 2010 RSA, as follows:

Third Landlord Note:  The first note (the “Third Landlord Note”) is a subordinated convertible note in the principal amount of $110,000. The Third Landlord Note carries no interest and is convertible, at Sinacola’s option, into the common stock of the Company at an exercise price of $1.00 per common share on the maturity date.

Fourth Landlord Note:  The second note (the “Fourth Landlord Note”) is a subordinated convertible note in the principal amount of $110,715. The Fourth Landlord Note carries no interest and is convertible into the common stock of the Company at an exercise price of $1.50 per common share on the maturity date.  However, if the common stock has traded at $1.50 or above for four (4) consecutive weeks on a nationally recognized market (based on daily closing prices) then the Fourth Landlord Note is convertible at the Company’s option.

Maturity Date – Each of the Third Landlord Note and the Fourth Landlord Note has a maturity date of October 31, 2012.

The Company also issued Sinacola with 143,465 penny warrants pursuant to the 2010 RSA (the “2010 Landlord Warrant”).  The 2010 Landlord Warrant is convertible into 143,465 shares of the Company’s common stock, and is exercisable in whole or in part at any time on or before December 31, 2015 at an exercise price of $.01 per share.
 
 
17

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)
 
In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the Third Landlord Note and the Fourth Landlord Note were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance. We recorded the relative fair value of the warrant issued in connection with the Third Landlord Note in the amount of $70,853 as a debt discount upon issuance, and amortized this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $39,147, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $15,000 and $15,000 for the three months ended June 30, 2012 and 2011, respectively in connection with the Third Landlord Note.  We recorded the relative fair value of the warrant issued in connection with the Fourth Landlord Note in the amount of $71,314 as a debt discount upon issuance, and amortized this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $34,409, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $14,417 and $14,417 for the three months ended June 30, 2012 and 2011, respectively in connection with the Fourth Landlord Note.
 
Fifth Landlord Note; Sixth Landlord Note:

On March 23, 2011 we entered into a third rent satisfaction agreement (the “2011 RSA”) with our landlord, Sinacola. In terms of the 2011 RSA, certain of our rent obligations for the period January 1, 2011 through June 30, 2011 under our lease agreement, including base rent and deferred rent, are satisfied in full.

We issued Sinacola two Promissory Notes pursuant to the 2011 RSA, as follows:

Fifth Landlord Note:  The first note (the “Fifth Landlord Note”) is a subordinated convertible note in the principal amount of $50,000. The Fifth Landlord Note carries no interest and is convertible, at Sinacola’s option, into the common stock of the Company at an exercise price of $1.00 per common share on the maturity date.
 
 
18

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

Sixth Landlord Note:  The second note (the “Sixth Landlord Note”) is a subordinated convertible note in the principal amount of $50,000. The Sixth Landlord Note carries no interest and is convertible into the common stock of the Company at an exercise price of $1.50 per common share on the maturity date.  However, if the common stock has traded at $1.50 or above for four (4) consecutive weeks on a nationally recognized market (based on daily closing prices) then the Sixth Landlord Note is convertible at the Company’s option.

Maturity Date – Each of the Fifth Landlord Note and the Sixth Landlord Note has a maturity date of September 30, 2013.

We also issued Sinacola with 65,000 penny warrants pursuant to the 2011 RSA (the “2011 Landlord Warrant”).  The 2011 Landlord Warrant is convertible into 65,000 shares of our common stock, and is exercisable in whole or in part at any time on or before March 23, 2016 at an exercise price of $.01 per share.
 
In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the Fifth Landlord Note and the Sixth Landlord Note were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance. We recorded the relative fair value of the warrant issued in connection with the Fifth Landlord Note in the amount of $32,207 as a debt discount upon issuance, and amortized this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $17,793, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $6,250 and $6,250 for the three months ended June 30, 2012 and 2011, respectively in connection with the Fifth Landlord Note.  We recorded the relative fair value of the warrant issued in connection with the Sixth Landlord Note in the amount of $32,207 as a debt discount upon issuance, and amortized this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $15,540, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $5,968 and $5,968 for the three months ended June 30, 2012 and 2011, respectively in connection with the Sixth Landlord Note.
 
Seventh Landlord Note; Eighth Landlord Note:

On August 15, 2011 we entered into a fourth rent satisfaction agreement (the “Second 2011 RSA”) with our landlord, Sinacola. In terms of the Second 2011 RSA, certain of our rent obligations for the period July 1, 2011 through December 31, 2011 under our lease agreement, including base rent and deferred rent, are satisfied in full.

We issued Sinacola two Promissory Notes pursuant to the Second 2011 RSA, as follows:

Seventh Landlord Note:  The first note (the “Seventh Landlord Note”) is a subordinated convertible note in the principal amount of $50,050. The Fifth Landlord Note carries no interest and is convertible, at Sinacola’s option, into the common stock of the Company at an exercise price of $1.00 per common share on the maturity date.

Eighth Landlord Note:  The second note (the “Eighth Landlord Note”) is a subordinated convertible note in the principal amount of $50,050. The Eighth Landlord Note carries no interest and is convertible into the common stock of the Company at an exercise price of $1.50 per common share on the maturity date.  However, if the common stock has traded at $1.50 or above for four (4) consecutive weeks on a nationally recognized market (based on daily closing prices) then the Sixth Landlord Note is convertible at the Company’s option.
 
 
19

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

Maturity Date – Each of the Seventh Landlord Note and the Eighth Landlord Note has a maturity date of November 30, 2013.

We also issued Sinacola with 65,065 penny warrants pursuant to the Second 2011 RSA (the “Second 2011 Landlord Warrant”).  The Second 2011 Landlord Warrant is convertible into 65,065 shares of our common stock, and is exercisable in whole or in part at any time on or before August 15, 2016 at an exercise price of $.01 per share.
 
In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the Seventh Landlord Note and the Eighth Landlord Note were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance. We recorded the relative fair value of the warrant issued in connection with the Seventh Landlord Note in the amount of $32,223 as a debt discount upon issuance, and we amortize this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $17,827, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $5,460 and $0 for the three months ended June 30, 2012 and 2011, respectively in connection with the Seventh Landlord Note.  We recorded the relative fair value of the warrant issued in connection with the Eighth Landlord Note in the amount of $32,223 as a debt discount upon issuance, and we amortize this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrant with the subordinated convertible promissory note, a beneficial conversion option was recorded as a debt discount reflecting the incremental conversion option intrinsic value benefit of $15,540, at the time of issuance provided to the holder of the note, which we also amortize as interest expense over the life of the note. We recorded interest expense in the amounts of $5,210 and $0 for the three months ended June 30, 2012 and 2011, respectively in connection with the Eighth Landlord Note.
 
 
20

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

The following table reflects the carrying values of our short-term and long-term notes payable as of June 30, 2012:
 
   
Effective Interest Rate
   
Principal
   
Discount
   
June 30, 2012
 
                         
Current notes payable
                       
JTR, Senior Note
    0.00 %   $ 1,018,656     $ -     $ 1,018,656  
Sinacola, Third Landlord Note
    54.55 %     110,000       20,000       90,000  
Sinacola, Fourth Landlord Note
    52.09 %     110,715       19,222       91,494  
Sinacola, Fifth Landlord Note
    50.00 %     50,000       18,194       31,806  
Sinacola, Sixth Landlord Note
    47.75 %     50,000       17,375       32,625  
Frisco EDC
    12.34 %     39,000       6,206       32,794  
Agave, First Note
    0.00 %     750,000       -       750,000  
JTR, Second Note
    0.00 %     250,000       -       250,000  
Other indebtedness
    0.00 %     68,694       -       68,694  
                                 
Total short-term notes payable
          $ 2,447,065     $ 80,997     $ 2,366,068  
                                 
Long-term notes payable
                               
                                 
Sinacola, Seventh Landlord Note
    43.64 %   $ 50,050     $ 32,760     $ 17,290  
Sinacola, Eighth Landlord Note
    41.64 %     50,050       31,263       18,787  
Frisco EDC
    12.34 %     148,000       40,340       107,660  
                                 
Total long-term notes payable
          $ 248,100     $ 104,363     $ 143,737  
Total short-term and long-term notes payable
          $ 2,695,165     $ 185,360     $ 2,509,805  
 
 
21

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 4 – NOTES PAYABLE (CONTINUED)

The following table summarizes our outstanding notes payable as of June 30, 2012 and December 31, 2011:

   
June 30,
2012
   
December 31,
2011
 
             
Current portion of notes payable
  $ 101,488     $ 86,338  
Current portion of convertible notes payable
    2,264,581       1,478,722  
Current portion of notes payable, net
  $ 2,366,068     $ 1,565,059  
                 
Long-term portion of notes payable
  $ 148,000     $ 154,380  
Less: Unamortized discount
    (40,340 )     (46,720 )
      107,660       107,660  
                 
                 
Long-term portion of convertible notes payable
  $ 100,100     $ 1,200,100  
Less: Unamortized discount
    (64,023 )     (145,370 )
      36,077       1,054,730  
                 
Long-term portion of total notes payable, net
  $ 143,737     $ 1,162,390  
 
 
22

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 5 - SHAREHOLDERS’ EQUITY

Preferred Shares Rights

On December 31, 2005, the Company’s Board of Directors adopted a Preferred Shares Rights Agreement (the “Original Rights Agreement”).   Pursuant to the Agreement, the Board authorized the issuance of up to 5,000,000 shares of preferred stock, par value $0.0005 per share. As of June 30, 2012, the Company had authorized the issuance of 3,143,237 shares of preferred stock designated as Series A Convertible Preferred Stock (“Series A Preferred”). The original issue price of the Series A Preferred is $1.00 per share. There were 1,118,750 and 3,126,434 Series A Preferred shares issued and outstanding as of June 30, 2012 and December 31, 2011, respectively.

During the three months ended June 30, 2012 the Company did not issue any shares of the Series A Preferred. During the three months ended June 30, 2012 approximately 200,000 shares of the Series A Preferred have been converted into approximately 244,000 shares of our common stock at a conversion ratio of 1.22:1.

A summary of the designations and preferences of its Series A Preferred stock is as follows:

Ranking – The Series A Preferred ranks senior to common stock.
Dividends – Series A Preferred may be entitled to receive a quarterly non-cumulative dividend in the amount of $.01 per share upon approval from the Board of Directors.
Liquidation Preference – In the event of any liquidation, dissolution, or winding up of the Company, the holders of Series A Preferred are entitled to receive 100% of the original issue price of $1.00 per share.
Conversion Rights – Each share of Series A Preferred is convertible at any time, at the option of the holder into 1.22 shares of common stock, subject to adjustment. Series A Preferred are subject to automatic conversion upon consummation of underwritten offering by the Company of shares of common stock to the public, in which the aggregate cash proceeds are at least $3 million and the price paid per share is at least $5.00.
Redemption Rights – All of the Series A Preferred may be called at any time by the Company within ten years, but not prior to two years after issuance. The redemption value is $1.00 per share, plus an amount equal to all unpaid dividends thereon.
Voting Rights – The holder of each share of Series A Preferred has the right to one vote for each share of common stock into which such share of Series A Preferred could be converted.
 
 
23

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 5 - SHAREHOLDERS’ EQUITY (CONTINUED)

Common Stock

The Company has authorized 100,000,000 shares of $0.0004 par value common stock.

During the three months ended June 30, 2012 we issued:

  
Approximately 244,000 shares of our common stock pursuant to the conversion of approximately 200,000 shares of our Series A Convertible Preferred Stock at a conversion ratio of 1.22:1;
  
Approximately 356,474 shares of our common stock pursuant to the exercise of options at an aggregate exercise price of $.25 per share;
  
Approximately 882,616 shares of our common stock pursuant to the exercise of warrants at an aggregate exercise price of $.10 per share; and
  
Approximately 116,212 shares of our common stock pursuant to the conversion of notes at an aggregate conversion price of $1.11 per share.  

As of June 30, 2012 we had 20,533,812 shares of common stock issued and outstanding.
 
NOTE 6 - STOCK OPTIONS AND WARRANTS

Equity Incentive Plans

In April 2004, our Board of Directors and the stockholders at that time approved the adoption of a Voting Stock Option Plan (“the Plan”), which provides for the issuance of stock options to eligible employees, consultants, Board members and Advisory Board members of the Company to acquire up to a maximum of 5,000,000 shares of common stock.

Our Board of Directors, which determines the number of options that will be granted, the effective dates of the grants, the option process and the vesting schedules, administers the Plan. In the absence of an established market for the common stock of the Company, the Board of Directors determines the fair market value of our common stock. Options generally expire between five and ten years from the date of grant and automatically terminate 90 days after such optionee ceases to be an eligible individual under the Plan other than by reason of death or disability.

The portion of options granted that is not exercisable on the date the optionee ceases to be an eligible individual under the Plan by reason other than death, shall terminate and be forfeited to the Company on the date of such cessation. An optionee has no right as a stockholder with respect to any shares covered by the options granted to him until a certificate representing such shares is issued to them.

Stock Options

The following table summarizes information about the number and weighted average of the options that were forfeited or expired under the Plan as at June 30, 2012:

   
Employee
   
Non-Employee
       
         
Weighted
         
Weighted
       
   
Number
   
Average
   
Number
   
Average
   
Combined
 
   
Of
   
Exercise
   
Of
   
Exercise
   
Total
 
   
Options
   
Price
   
Options
   
Price
   
Options
 
Outstanding at March 31, 2012
    1,890,574     $ 0.44       53,180     $ 0.72       1,943,754  
Granted
    -     $ -       -     $ -       -  
Exercised
    (356,474 )   $ 0.25       -     $ -       (356,474 )
Forfeited/Cancelled
    (32,750 )   $ 2.23       -     $ -       (32,750 )
Outstanding at June 30, 2012
    1,501,350     $ 0.42       53,180     $ 0.72       1,554,530  
 
 
24

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 6 - STOCK OPTIONS AND WARRANTS (CONTINUED)

We used the following assumptions to estimate the fair value of options granted under the Plan for the three months ended June 30, 2012 and 2011:
 
   
Equity Incentive Plans for Periods
Ended June 30,
 
   
2012
   
2011
 
             
Expected terms (in years)
    5-10       5-10  
Volatility (weighted ave.)
    26 %     25 %
Risk-free interest rate (weighted ave.)
    1.04 %     0.72 %
Expected dividend rate
    0.00 %     0.00 %
 
Risk-Free Interest Rate
 
The risk-free interest rate assumption was based on U.S. Treasury instruments with a term that is consistent with the expected term of our stock options.
Expected Volatility
We use historical volatility in deriving our expected volatility assumption because we believe that future volatility over the expected term of the stock options is not likely to differ from the past.
 
Expected Term
The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding. The expected term is based on the observed and expected time to exercise and post-vesting cancellations of options by optionees.  We use historical volatility in deriving our expected volatility assumption because it believes that future volatility over the expected term of the stock options is not likely to differ from the past.
 
Expected Dividend Yield
The expected dividend yield of 0% is based on our history and expectation of dividend payouts. We have not paid and do not anticipate paying any dividends in the near future.
 
Forfeitures
FASB ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.  We only record stock-based compensation expense for awards that are expected to vest. While we generally consider historical forfeitures in its estimates, judgment is also required in estimating the amount of stock-based awards that are expected to be forfeited. Our estimate for forfeitures may differ from actual forfeitures. If actual results differ significantly from these estimates, stock-based compensation expense and our results of operations could be materially impacted when we record a true-up for the difference in the period that the awards vest.  We adjust stock-based compensation expense based on our actual forfeitures on an annual basis, if necessary.
 
As of June 30, 2012, there were unrecognized compensation costs of approximately $72,125 related to non-vested stock option awards granted after April 2004 that will be recognized on a straight-line basis over the weighted average remaining vesting period of 0.58 years.

Stock compensation cost, using the graded vesting attribute method in accordance with Codification topic 718, is recognized over the requisite service period, generally 5 years, during which each tranche (one fifth) of shares is earned (zero, one, two, three, and four years).  The value of each tranche is amortized on a straight-line basis.  For the three months ended June 30, 2012, stock based compensation expense was approximately $7,695, which consisted primarily of stock-based compensation expense related to stock options recognized under GAAP issued to employees.  For the three months ended June 30, 2012, there were 356,474 options exercised at an aggregate exercise price of $.25 per share.
 
 
25

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 6 - STOCK OPTIONS AND WARRANTS (CONTINUED)
 
Warrants.

The following table summarizes our warrant activities for the three months ended June 30, 2012:

         
Weighted
 
   
Number
   
Average
 
   
Of
   
Exercise
 
   
Warrants
   
Price
 
Outstanding at March 31, 2012
    2,754,650     $ 0.48  
Granted
    -     $ -  
Exercised
    (882,616 )   $ 0.10  
Forfeited/Cancelled
    -     $ -  
Outstanding at June 30, 2012
    1,872,034     $ 0.66  
 
NOTE 7 – INCOME TAXES

No content available.

NOTE 8 – LICENSE AND SERVICE AGREEMENTS

No content available.

NOTE 9 – COMMITMENTS AND CONTINGENCY

Leases

Operating Lease – We lease our office and manufacturing space under an operating lease that includes fixed annual increases and expires in September 2012. Total rent expense was $28,932 and $28,932 for the three months ended June 30, 2012 and 2011, respectively.

Capital lease – We lease certain equipments under capital lease agreements that expire at various dates through 2012. Total Capital lease obligations were $326,699 and $330,571 as at June 30, 2012 and December 31, 2011, respectively.

Legal Proceedings

The Company is subject to litigation in the normal course of business. As of June 30, 2012 the Company was not a party to any ongoing litigation matters.
 
 
26

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 9 – COMMITMENTS AND CONTINGENCY (CONTINUED)

Indemnification

Under the indemnification provisions of our customer agreements, we routinely agree to indemnify and defend our customers against infringement of any patent, trademark, or copyright of any country or the misappropriation of any trade secret, arising from the customers’ legal use of our products or services. The exposure to us under these indemnification provisions is generally limited to the total amount paid by the customers under pertinent agreements. However, certain indemnification provisions potentially expose us to losses in excess of the aggregate amount received from the customer. To date, there have been no claims against us or our customers pertaining to such indemnification provisions and no amounts have been recorded.

NOTE 10 – RELATED PARTY TRANSACTIONS

As discussed in Note 4, “Notes Payable” several of the notes payable are entered among related parties.

A summary of the related party financings and notes as at June 30, 2012 is as follows:

   
First Note
   
Second Note
   
Senior Note
   
Other
 
Holder
 
Agave Resources, LLC(1)
   
JTR Investments, Limited(2)
   
JTR Investments, Limited(2)
   
Related Party
 
Amount
  $ 750,000     $ 250,000     $ 1,018,656     $ 68,694  
Stated interest rate
    0 %     0 %     0 %     0 %
Maturity
 
4/15/2013
   
4/15/2013
   
Current
   
Current
 
Warrants issued (Please see Note 6 – “Stock Options & Warrants” for warrant details)
    350,000       116,667       572,503       -  

(1) Agave Resources, LLC is controlled by one of our Directors, Donald Reed.
(2) JTR Investments, Ltd. is a limited partnership controlled by our President and CEO, Julian Ross.
 
 
27

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 11 – NET INCOME (LOSS) PER SHARE

The following table sets forth the computation of net basic and diluted net income (loss) per share:

   
Three months ended June 30,
 
Historical net loss per share:
 
2012
   
2011
 
             
Net income (loss)
    (218,472 )     (463,371 )
Shares used in computing basic per share amounts (weighted average)
    19,807,432       15,749,756  
Net income (loss) per share:
               
Basic and Diluted
  $ (0.01 )   $ (0.03 )
 
NOTE 12 – FAIR VALUE MEASUREMENTS

Effective January 1, 2009, the Company adopted new fair value accounting guidance. The adoption of the guidance was limited to financial assets and liabilities and did not have a material effect on the Company’s financial condition or results of operations.
 
The guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact business and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. The guidance establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The guidance establishes three levels of inputs that may be used to measure fair value:
 
Level 1 — Quoted prices in active markets for identical assets or liabilities.
 
Level 2 — Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities.
 
 
28

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 12 – FAIR VALUE MEASUREMENTS (CONTINUED)
 
Level 3 — Unobservable inputs to the valuation methodology that is significant to the measurement of fair value of assets or liabilities.

Assets Measured at Fair Value on a Recurring Basis

The following table presents the Company’s financial assets and liabilities that are measured at fair value on a recurring basis which were comprised of the following types of instruments as of June 30, 2012:

   
Total
   
Level 1
   
Level 2
   
Level 3
 
                         
Cash (1)
 
$
22,152
   
$
22,152
     
-
     
-
 
Total cash equivalents as of June 30, 2012
 
$
22,152
   
$
22,152
   
$
-
   
$
-
 
 
(1) Included in cash and cash equivalents on the Company's Balance Sheet.
 
NOTE 13 – OFF BALANCE SHEET ARRANGEMENTS AND CONTRACTUAL OBLIGATIONS
 
We have not entered into any transactions with unconsolidated entities whereby we have financial guarantees, subordinated retained interests, or other contingent arrangements that expose us to material continuing risks, contingent liabilities, or any other obligation under a variable interest in an unconsolidated entity that provides financing, liquidity, market risk or credit risk support to us.
 
NOTE 14 – SEGMENT INFORMATION
 
We are organized as, and operate in, one reportable segment: the development, distribution and sale of specialty respiratory products and related medical products and accessories. Our chief operating decision-maker is our Chief Executive Officer. Our Chief Executive Officer reviews financial information presented on a consolidated basis for purposes of evaluating financial performance and allocating resources, accompanied by information about revenue by geographic regions. Our assets are primarily located in the United States of America and not allocated to any specific region and we do not measure the performance of our geographic regions based upon asset-based metrics. Therefore, geographic information is presented only for revenue. Revenue by geographic region is based on the ship to address on our customer orders.
 
 
29

 
 
OXYSURE SYSTEMS, INC.
NOTES TO FINANCIAL STATEMENTS
JUNE 30, 2012
(Unaudited)
 
NOTE 14 – SEGMENT INFORMATION (CONTINUED)
 
The following presents total revenue by geographic region for the three month periods ended June 30, 2012 and 2011:

   
Three Months Ended June 30,
 
   
2012
   
2011
 
             
Revenues:
           
United States - product sales
  $ 18,091     $ 32,120  
ROW - product sales
    44,800       30,402  
        Total revenues
  $ 62,891     $ 62,522  
 
NOTE 15 – GOING CONCERN

Our financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  We have been suffering from recurring losses from operations. We have an accumulated deficit of $13,974,618 and $13,430,659 at June 30, 2012 and December 31, 2011, respectively, and stockholders’ deficits of $2,828,472 and $2,777,139 as of June 30, 2012 and December 31, 2011, respectively. We require substantial additional funds to manufacture and commercialize our products. Our management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.
 
In view of the matters described above, recoverability of a major portion of the recorded asset amounts shown in the accompanying June 30, 2012 balance sheet is dependent upon continued operations of the Company, which in turn is dependent upon the Company’s ability to meet its financing requirements on a continuing basis, to maintain present financing, and to generate cash from future operations. These factors, among others, raise doubt about our ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should we be unable to continue in existence.
 
We have a series of plans to mitigate the going concern:
 
1. We have a line of credit in place - the JTR Senior Note, which allows us to draw down up to $2,000,000. As at June 30, 2012 we had approximately $981,344 available under this facility. Please see Note 4 - “Notes Payable” for details regarding the JTR Senior Note.
 
2. Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.
 
3. We anticipate that sales during the remainder of 2012 and 2013 from existing markets will grow, and we believe that we will be able to generate sales from new markets. Existing markets include education customers such as schools, school districts and colleges, and commercial customers such as manufacturing facilities, churches and other commercial venues. New markets will include, but not be limited to, government customers and new international territories and markets.
 
4. We plan to increase our market penetration through the addition of new distributors.
 
5. We plan to continue to diversify our product range through the addition of complementary products and solutions. Some of these products will be sourced from third party manufacturers and suppliers.
 
NOTE 16 - SUBSEQUENT EVENTS

Second Payment Moratorium with Vencore Solutions, LLC:  

On July 9, 2012 we entered into a second moratorium agreement (“Second Payment Moratorium”) with Vencore Solutions, LLC, a Delaware limited liability company (“Vencore”).

The Second Payment Moratorium provides for the following:

a) 
The balance outstanding to Vencore remains the balance outstanding at the end of the first payment moratorium, which is $307,661.83 (“Debt Obligation”);
b) 
The term of the Second Payment Moratorium (the “Moratorium Period”) shall expire on the earlier to occur of: (i) July 1, 2013;  (ii) a cash settlement or repayment plan being entered into; or (iii) a merger or acquisition of us or the sale of substantially all of its assets (collectively a “Sale”);
c) 
We will not be obligated to make any payments during the Moratorium Period;
d) 
No late charges or interest will accrue during the Moratorium Period;
e) 
Any amounts we may pay towards the Debt Obligation during the Moratorium Period shall reduce the Debt Obligation;
f)
In the event of a Sale the entire Debt Obligation shall immediately become due and payable; and
g) 
Vencore shall make no demands or take any actions against us during the Moratorium Period.

In exchange for the Second Payment Moratorium, we agreed to issue to Vencore two warrants (the “Warrants”) as follows:

a)  
A warrant as to 22,500 common shares at an exercise price per share of $0.82; and
b)  
A warrant as to 32,500 common shares at an exercise price per share of $1.00.

The terms of the Warrants shall be 5 years each and Vencore shall have the ability to exercise the Warrants on a cashless/net-issuance basis.
 
 
30

 
 
NOTE 17 – CORRECTION OF ERROR TO PRIOR PERIOD FINANCIAL STATEMENTS

The financial statements for the quarter ended June 30, 2011 have been restated as further outlined below:

   
Three Months Ended June 30, 2011
 
                         
   
As
         
Restatement
   
As
 
   
Reported
         
Adjustment
   
Restated
 
                         
Statement of Operations:
                       
                         
Revenues, net
    46,687       a)       15,835       62,522  
                                 
Cost of Goods Sold
    22,271       a)       9,666          
              b)       (5 )     31,932  
                                 
Net Loss
    (469,540 )     a)       6,169       (463,371 )
                                 
                                 
Accumulated deficit - beginning of the period
  $ (12,266,175 )     a)       (6,169 )   $ (12,272,344 )
                                 
Accumulated deficit - end of the period
  $ (12,735,715 )             -       (12,735,715 )
                                 
                                 
Basic net loss per common share
  $ 0.03             $ -     $ (0.03 )
Diluted net loss per common share
  $ 0.03             $ -     $ (0.03 )
 
a) During the quarter ended March 31, 2011 the Company erroneously recorded $15,835 in revenues related to a second quarter 2011 shipment to an international customer, resulting in a period timing difference. Therefore, the correction increased the revenues for the three months ended June 30, 2011 by $15,835. This adjustment reconciles the activity for revenues, cost of goods sold, and inventory.  The net result of this adjustment caused an increase in revenues, an increase in cost of goods sold, a decrease in net loss, a decrease in inventory, and a decrease in accumulated deficit during the three months ended June 30, 2011; these changes offset the same changes during three months ended March 31, 2011. There was no change in basic net loss per common share or diluted net loss per common share.
 
b) This entry reflects all income statement adjustments to accumulated deficit for the three months ended June 30, 2011.
 
 
31

 
 
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
The following discussion and analysis should be read in conjunction with our financial statements, including the notes thereto, appearing elsewhere in this report.

Overview

OxySure Systems, Inc. was formed on January 15, 2004 as a Delaware “C” Corporation for the purpose of developing products with the capability of generating medical grade oxygen “on demand,” without the necessity of storing oxygen in compressed tanks.  We developed a unique technology that generates medically pure (USP) oxygen from two dry, inert powders.  Other available chemical oxygen generating technologies contain hazards that we believe make them commercially unviable for broad-based emergency use by lay rescuers or the general public.  Our launch product is the OxySure Model 615 portable emergency oxygen system.  We believe that the OxySure Model 615 is currently the only product on the market that can be safely pre-positioned in public and private venues for emergency administration of medical oxygen by lay persons, without the need for training.

Critical Accounting Policies

The SEC defines critical accounting policies as those that are, in management's view, most important to the portrayal of our financial condition and results of operations and those that require significant judgments and estimates.
 
The discussion and analysis of our financial condition and results of operations is based upon our financial statements which have been prepared in accordance with accounting principles generally accepted in the United States.  The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities.  On an on-going basis, we evaluate our estimates including the allowance for doubtful accounts, the salability and recoverability of inventory, income taxes and contingencies.  We base our estimates on historical experience and on other assumptions that we believe to be reasonable under the circumstances, the results of which form our basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources.  Actual results may differ from these estimates under different assumptions or conditions.
 
We cannot predict what future laws and regulations might be passed that could have a material effect on our results of operations.  We assess the impact of significant changes in laws and regulations on a regular basis and update the assumptions and estimates used to prepare our financial statements when we deem it necessary.
 
Revenue Recognition.  Our revenue recognition policies are in accordance with the SEC Staff Accounting Bulletin (SAB) No. 104.  Sales revenue is recognized at the date of shipment to customers when a formal arrangement exists, the price is fixed or determinable, shipment has occurred, no other significant obligations on our part exist and collectability is reasonably assured.  Revenues are recognized from product sales, net of discounts and rebates.  This revenue recognition policy is applied to both customers and distributors.  Fees from licensees desiring to manufacture and distribute our products or derivative products using our intellectual property include initial license fees and royalties.  Initial license fees are generally recognized upon granting of the license to the licensee.  Royalties are recognized in the period earned.
 
 
32

 
 
Allowance for doubtful accounts.  We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of the Company’s customers to make payments.  The Company periodically reviews these allowances, including an analysis of the customers’ payment history and information regarding the customers’ creditworthiness.  Actual write-offs have not been materially different from the estimated allowance.  Our accounts receivable represent a significant portion of our current assets and total assets.
 
Inventories.  Our inventory consists of raw material and components for our portable oxygen systems as well as completed products and accessories.  Inventories are computed using the lower of cost or market, which approximates actual cost on a first-in first-out basis.  Inventory components are parts, work-in-process and finished goods.  Finished goods are reported as inventories until the point of title transfer to our customers.  We write down our inventory value for estimated obsolescence equal to the difference between the cost of inventory and the estimated market value based upon assumptions about future demand and market conditions.  These factors are impacted by market and economic conditions, technology changes, new product introductions and changes in strategic direction and require estimates that may include uncertain elements.  Actual demand may differ from forecasted demand, and such differences may have a material effect on recorded inventory values.  Management has established inventory reserves to cover estimated inventory losses for all work-in-process and finished goods related to products we manufactured, as well as raw material and components for those products that had no potential use in products to be manufactured in the future.  Management was required to make judgments about the future benefit of our raw materials and components.  Actual reserve requirements could differ significantly from management’s estimates, which could have a significant unfavorable impact on our future gross margins.
 
Cash and Cash Equivalents.  We sell our products throughout the United States as well as in certain other countries.  Sales to its recurring customers in the United States are generally granted on net 30-day credit terms. We perform periodic credit evaluations of our recurring customers and generally do not require collateral. In general, we require prepayment on all sales to customers outside the United States. An allowance for doubtful accounts is maintained for potential credit losses, which losses historically have not been significant.

We invest our cash in deposits and money market funds with major financial institutions.  We place our cash investments in instruments that meet high credit quality standards, as specified in our investment policy guidelines. These guidelines also limit the amount of credit exposure to any one issue, issuer or type of instrument.
 
Property and Equipment.  Property and equipment are recorded at cost with depreciation and amortization provided over the shorter of the remaining lease term or the estimated useful life of the improvement ranging from three to seven years. Renewals and betterments that materially extend the life of an asset are capitalized. Expenditures for maintenance and repairs are charged to expense when incurred. Furniture and fixtures are depreciated over five years. Machinery and equipments are depreciated over five to seven years. Software is depreciated over three years.  Leasehold improvements are computed using the shorter of the estimated useful lives of the assets or the lease terms.  Depreciation expense was $40,314 and $44,065 for the three month periods ended June 30, 2012 and 2011, respectively.
 
 
33

 
 
Impairment of Long-Lived Assets.  We review long-lived assets, including amortizable intangibles, for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable.  If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, a loss is recognized for the difference between the fair value and carrying value of the asset.  During the three months ended June 30, 2012, we did not recognize any impairment charge.
 
Research and Development Costs.  Costs associated with the development of our products are charged to expense as incurred.  $1,175 and $60 were incurred in the three month periods ended June 30, 2012 and 2011, respectively.
 
Income Taxes.  In accordance with Accounting Standards Codification (“ASC”) Topic 740, “Income Taxes” (“ASC 740”), we account for income taxes using an asset and liability approach, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in our Consolidated Financial Statements, but have not been reflected in our taxable income.  A valuation allowance has been established to reduce deferred tax assets to their estimated realizable value.  Therefore, we provide a valuation allowance to the extent that we do not believe it is more likely than not that we will generate sufficient taxable income in future periods to realize the benefit of our deferred tax assets.  We recognize interest and penalties related to unrecognized tax benefits in income tax expense.
 
Equity Warrants.  We have issued warrants to purchase shares of our common stock in connection with convertible notes.  In accordance with ASC 470-20, Debt with conversions and other options, the proceeds from the notes were allocated based on the relative fair values of the notes without the warrants issued in conjunction with the notes and of the warrants themselves at the time of issuance.  We record the fair value of the warrants at the time of issuance as additional paid in capital and as a debt discount to the notes.  We amortize this debt discount as interest expense over the life of the note.  Additionally, as a result of issuing the warrants with the convertible notes, a beneficial conversion option is recorded as a debt discount reflecting the incremental conversion option intrinsic value of the conversion option provided to the holders of the notes.  We also amortize this debt discount as interest expense over the life of the notes.  The intrinsic value of each conversion option was calculated as the difference between the effective conversion price and the fair value of the common stock, multiplied by the number of shares into which the note is convertible.
 
Stock-Based Compensation.  We account for share-based payments, including grants of stock options to employees, consultants and non-employees; moreover, we issue warrants to the consultants and related parties.  We are required to estimate the fair value of share-based awards and warrants on the date of grant.  The value of the award is principally recognized as expense ratably over the requisite service periods.  We have estimated the fair value of stock options and warrants as of the date of grant or assumption using the Black-Scholes option pricing model, which was developed for use in estimating the value of traded options that have no vesting restrictions and that are freely transferable.  The Black-Scholes model requires the input of certain assumptions.  Changes in the assumptions used in Black-Scholes model can materially affect the fair value estimates. With the exception of forfeiture rates, which we evaluate annually, we evaluate the assumptions used to value stock options on a quarterly basis.  The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding.
 
 
34

 
 
The expected term is based on the observed and expected time to exercise and post-vesting cancellations of options by employees.  Upon the adoption of the accounting guidance, we continue to use historical volatility in deriving our expected volatility assumption as allowed under GAAP because we believe that future volatility over the expected term of the stock options is not likely to differ materially from the past.  The risk-free interest rate assumption is based on the five-year U.S. Treasury zero-coupon rate appropriate for the expected term of the stock options.  The expected dividend assumption is based on the history and expectation of dividend payouts.  The fair values generated by the Black-Scholes model may not be indicative of the actual fair values of the equity awards, as we do not consider other factors important to those awards to employees, such as continued employment, periodic vesting requirements and limited transferability.  The amount of stock based compensation expenses is net of an estimated forfeiture rate, which we adjust on an annual basis, if at all, and which is based on historical data and information from comparable companies, and our judgment of whether the options are expected to vest.  For the three month periods ended June 30, 2012 and 2011, stock based compensation expense was approximately $7,695 and $5,056, respectively, which consisted primarily of stock-based compensation expense related to stock options issued to the employees and recognized under GAAP.
 
We follow ASC Topic 505-50, formerly EITF 96-18, “Accounting for Equity Instruments that are Issued to Other than Employees for Acquiring, or in Conjunction with Selling Goods and Services,” for stock options and warrants issued to consultants and other non-employees.  In accordance with ASC Topic 505-50, these stock options and warrants issued as compensation for services to be provided to us are accounted for based upon the fair value of the services provided or the estimated fair market value of the option or warrant, whichever can be more clearly determined.  We recognize this expense over the period in which the services are provided.  For each of the three month periods ended June 30, 2012 and 2011, stock based compensation expense was approximately $0, which consisted primarily of stock-based compensation expense related to stock options and warrants recognized under GAAP issued to consultants and other non-employees.
 
Accounting Estimates.  The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amount of revenues and expenses during the reported period.  Actual results could differ from those estimated.
 
 
35

 
 
Advertising Costs.  Advertising costs are charged to operations when incurred.  We incurred $18,134 and $0 in advertising and promotion costs during the three month periods ended June 30, 2012 and 2011, respectively.
 
Financial Instruments.  Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of June 30, 2012.  The respective carrying values of certain balance sheet financial instruments approximate their fair values.  These financial instruments include cash, accounts payable, accrued expenses and notes payable.  Fair values were assumed to approximate carrying values for these financial instruments because they are short term in nature and their carrying amounts approximate fair values.
 
Restatements and Reclassifications.  Certain financial statement items have been reclassified to conform to the current periods’ presentation. These reclassifications had no impact on previously reported net loss. Certain financial statement items for the quarter ended June 30, 2011 have been restated - please see Note 17 - "Correction of error to prior period financial statements" to our financial statements.
 
Recently Enacted Accounting Standards.  In June 2011, the Financial Accounting Standards Board, or FASB, issued guidance regarding the presentation of comprehensive income. The new standard requires the presentation of comprehensive income, the components of net income and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. The new standard also requires presentation of adjustments for items that are reclassified from other comprehensive income to net income in the statement where the components of net income and the components of other comprehensive income are presented. The updated guidance is effective on a retrospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. The adoption of this guidance will not have a material impact on our financial statements.

In May 2011 the FASB issued additional guidance on fair value measurements that clarifies the application of existing guidance and disclosure requirements, changes certain fair value measurement principles and requires additional disclosures about fair value measurements. The updated guidance is effective on a prospective basis for financial statements issued for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2011. The adoption of this guidance will not have a material impact on our financial statements.

In September 2011 the FASB issued new accounting guidance intended to simplify goodwill impairment testing. Entities will be allowed to perform a qualitative assessment on goodwill impairment to determine whether a quantitative assessment is necessary. This guidance is effective for goodwill impairment tests performed in interim and annual periods for fiscal years beginning after December 15, 2011. Early adoption is permitted. The adoption of this guidance will not have a material impact on our financial statements.

Results of Operations

You should read the selected financial data set forth below along with our discussion and our financial statements and the related notes. We have derived the financial data from our unaudited financial statements. We believe the financial data shown in the table below include all adjustments consisting only of normal recurring adjustments, that we consider necessary for a fair presentation of such information. Operating results for the period are not necessarily indicative of the results that may be expected in the future.
 
 
36

 
 
   
Three months ended June 30,
 
   
2012
   
2011
 
             
Revenues
  $ 62,891     $ 62,522  
Operating expenses
    256,754       265,336  
Net income (loss)
    (218,472 )     (463,371 )
Net income (loss) per share
  $ (0.01 )   $ (0.03 )
 
Results for the Three Months Ended June 30, 2012 Compared to the Three Months Ended June 30, 2011 (unaudited)

Revenues

We had $62,891 revenue from operations for the three months ended June 30, 2012 as compared to revenues of $62,522 for the three months ended June 30, 2011.  There was no significant change in revenues for the comparable periods.

Operating Expenses

Total expenses for the three months ended June 30, 2012 were $339,372, which amount includes $256,754 of selling, general and administrative expenses, $25,156 in cost of goods sold, and $57,462 in interest expense, as compared to total expenses for the three months ended June 30, 2011 of $525,890, which amount includes $265,336 of selling, general and administrative expenses, $31,932 in cost of goods sold, and $228,622 in interest expense.  The decrease in interest expense is primarily attributable to a decrease in interest expense related to convertible notes.

Research and Development
 
Research and development expenses of $1,175 and $60 were incurred in the three months periods ended June 30, 2012 and 2011, respectively.  There was fundamentally no change due to our limited budget during this period.

Net Loss

Net loss for the three months ended June 30, 2012 was $218,472 and diluted net loss per share was $0.01 as compared to a net loss for the three months ended June 30, 2011 of $463,371 and diluted net loss per share of $0.03.  The decrease in net loss per share is primarily due to a decrease in interest expense related to convertible notes.
 
 
37

 
 
Liquidity and Capital Resources

We had a cash balance of approximately $22,152 as of June 30, 2012, as compared to $76,947 as of June 30, 2011.  Our funds are kept in financial institutions located in the United States of America.
 
We had negative working capital of approximately $3,217,504 as of June 30, 2012 as compared to a negative working capital of $3,242,727 as of June 30, 2011.
 
We had total notes payable of $2,509,805 and $2,727,449 as of June 30, 2012 and December 31, 2011, respectively.  The decrease in Notes Payable was primarily due to a decrease in Long Term Notes Payable, from $1,162,390 to $143,737, offset by an increase in Current Notes Payable, from $1,565,059 to $2,366,068. The increase in Current Notes Payable is primarily due to a reclassification from Long Term Notes Payable of $1,000,000 in notes held by affiliates of us.
 
We generally provide our customers with terms of up to 30 days on our accounts receivable.  In some cases we require prepayment, depending on history or credit review.  Further, we generally require pre-payment on orders shipped to international destinations.  Our accounts receivable, net of allowances for sales returns and allowance for doubtful accounts, were $11,128 and $2,758 as at June 30, 2012 and December 31, 2011, respectively.
 
Since inception, we have been engaged primarily in product research and development, obtaining certain regulatory approvals, investigating markets for our products, developing manufacturing and supply chain partners, and developing distribution, licensing and other channel relationships.  In the course of funding research and development activities, we have sustained operating losses since inception and have an accumulated deficit of $13,974,618 at June 30, 2012.
 
We completed product development of our launch product, and launched sales thereof in 2008.  We have and will continue to use significant capital to manufacture and commercialize our products.  These factors raise doubt about our ability to continue as a going concern.  In this regard, management is proposing to raise any necessary additional funds not provided by operations through loans or through additional sales of our common stock.
 
During the remainder of 2012 and 2013, we will need additional capital to market and sell our products, and to further develop and enhance our current product offerings, introduce new products and address unanticipated competitive threats, technical problems, economic conditions or other requirements.  During the three months ended June 30, 2012 and 2011 we raised approximately $224,012 (net) and $6,500, respectively, through the exercise of warrants and stock options and the conversion of notes.  We estimate that we will require approximately $4.2 million over the next 12 months to remain viable.  There is no assurance that we will be successful in raising this additional capital or in achieving profitable operations.  The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.  However, there can be no assurance that any additional financing will be available to us.  Additional equity financing may involve substantial dilution to our then existing stockholders.  In the event we are unable to raise additional capital, we may be required to substantially reduce or curtail our activities.
 
 
38

 

ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.

ITEM 4.
CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Our President and Chief Financial Officer has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) as of the end of period covered by this report.  Based upon such evaluation,  the President and Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our President and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
 
39

 
 
PART II - OTHER INFORMATION

ITEM 1.
LEGAL PROCEEDINGS

The Company is subject to litigation in the normal course of business. As of June 30, 2012 the Company was not a party to any ongoing litigation matters.

ITEM 1A.
RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide information under this item.

ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
During the three months ended June 30, 2012 we issued:
  • Approximately 356,474 shares of our common stock pursuant to the exercise of options at an aggregate exercise price of $.25 per share, for total proceeds of $89,118.50;
  • Approximately 882,616 shares of our common stock pursuant to the exercise of warrants at an aggregate exercise price of $.10 per share, for total proceeds of $88,261.60; and
  • Approximately 116,212 shares of our common stock pursuant to the conversion of notes at an aggregate conversion price of $1.11 per share, for total proceeds of $128,995.32.
Proceeds from these transactions were used towards the reduction or exchange of debt and other obligations, for working capital and for general corporate purposes.
 
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.
(REMOVED AND RESERVED)
 
ITEM 5.
OTHER INFORMATION
 
None.

ITEM 6.
EXHIBITS

The following Exhibits are filed herein:                      
 
   
No.
 
             Title
 
   
31.1
 
Certification of President Pursuant to the Securities Exchange Act of 1934, Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

   
31.2
 
Certification of Chief Financial Officer Pursuant to the Securities Exchange Act of 1934, Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
         
   
32
 
Certifications Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
 
40

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
DATED: August 14, 2012
OXYSURE SYSTEMS, Inc.
 
     
 
/s/Julian T. Ross
 
 
BY: Julian T. Ross
 
 
ITS: President and Chief Financial Officer
 
 
(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)
 
 
41